Sangamo BioSciences SGMO today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy. A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in